The stock of 89bio Inc (ETNB) has seen a 13.40% increase in the past week, with a -19.11% drop in the past month, and a 8.92% flourish in the past quarter. The volatility ratio for the week is 8.21%, and the volatility levels for the past 30 days are at 6.96% for ETNB. The simple moving average for the past 20 days is -4.75% for ETNB’s stock, with a 1.31% simple moving average for the past 200 days.
Is It Worth Investing in 89bio Inc (NASDAQ: ETNB) Right Now?
The 36-month beta value for ETNB is also noteworthy at 1.22. There are mixed opinions on the stock, with 8 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for ETNB is 140.33M, and at present, short sellers hold a 6.88% of that float. The average trading volume of ETNB on March 19, 2025 was 2.30M shares.
ETNB) stock’s latest price update
The stock of 89bio Inc (NASDAQ: ETNB) has decreased by -1.72 when compared to last closing price of 8.70.Despite this, the company has seen a gain of 13.40% in its stock price over the last five trading days. zacks.com reported 2025-03-06 that Here is how 89BIO (ETNB) and Eton Pharmaceuticals, Inc. (ETON) have performed compared to their sector so far this year.
Analysts’ Opinion of ETNB
Many brokerage firms have already submitted their reports for ETNB stocks, with Goldman repeating the rating for ETNB by listing it as a “Neutral.” The predicted price for ETNB in the upcoming period, according to Goldman is $11 based on the research report published on March 14, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see ETNB reach a price target of $25. The rating they have provided for ETNB stocks is “Buy” according to the report published on March 13th, 2025.
ETNB Trading at -3.09% from the 50-Day Moving Average
After a stumble in the market that brought ETNB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.64% of loss for the given period.
Volatility was left at 6.96%, however, over the last 30 days, the volatility rate increased by 8.21%, as shares sank -21.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.14% upper at present.
During the last 5 trading sessions, ETNB rose by +13.40%, which changed the moving average for the period of 200-days by +6.61% in comparison to the 20-day moving average, which settled at $8.98. In addition, 89bio Inc saw 9.34% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ETNB starting from RA CAPITAL MANAGEMENT, L.P., who purchase 5,714,285 shares at the price of $8.75 back on Jan 30 ’25. After this action, RA CAPITAL MANAGEMENT, L.P. now owns 19,554,319 shares of 89bio Inc, valued at $49,999,994 using the latest closing price.
McWherter Charles, the Director of 89bio Inc, purchase 10,000 shares at $6.71 during a trade that took place back on Jan 22 ’25, which means that McWherter Charles is holding 25,000 shares at $67,100 based on the most recent closing price.
Stock Fundamentals for ETNB
The total capital return value is set at -0.87. Equity return is now at value -78.34, with -68.30 for asset returns.
Based on 89bio Inc (ETNB), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -9.8. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -72.71.
Currently, EBITDA for the company is -384.66 million with net debt to EBITDA at 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.19.
Conclusion
In summary, 89bio Inc (ETNB) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
